Company news

BioLineRX Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

September 10, 2026

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 27, 2026

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

May 20, 2026

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

April 28, 2026

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

April 8, 2026

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

March 26, 2026

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

March 23, 2026

BioLineRx to Report 2025 Annual Results on March 23, 2026

March 16, 2026

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

November 18, 2025

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

November 17, 2025

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

September 29, 2025

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

August 7, 2025

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 30, 2025

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 27, 2025

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

May 20, 2025

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

March 31, 2025

BioLineRx to Report 2024 Annual Results on March 31, 2025

March 24, 2025

Calls

The 5 newest of 15 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.